Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31444592 | 1.00 | TACR1 (0.46) | TACR1MEN1KMT2AGRIN2BHCRTR1 | |
| SCHEMBL4741235 | 0.80 | HTR2C (0.45) | TACR1GRIN2BHCRTR1HCRTR2OPRM1 | |
| SCHEMBL29589447 | 0.79 | MEN1 (0.65) | TACR1MEN1KMT2AHCRTR2HTR2C | |
| SCHEMBL469013 | 0.79 | MEN1 (0.65) | TACR1MEN1KMT2AHCRTR2HTR2C | |
| SCHEMBL23323077 | 0.79 | MEN1 (0.65) | TACR1MEN1KMT2AHCRTR2HTR2C | |
| SCHEMBL16796794 | 0.78 | TACR1 (0.46) | TACR1MEN1KMT2ACHRM5CHRM3 | |
| SCHEMBL31198369 | 0.78 | TACR1 (0.46) | TACR1MEN1KMT2ACHRM5CHRM3 | |
| SCHEMBL28907795 | 0.78 | MEN1 (0.48) | TACR1MEN1KMT2ACHRM5CHRM3 | |
| SCHEMBL11509481 | 0.76 | HTR1A (0.58) | TACR1MEN1KMT2ACHRM5CHRM3 | |
| SCHEMBL16455098 | 0.76 | HTR2A (0.53) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3889138-B1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | HINOVA PHARMACEUTICALS INC (CN) | 2024-11-20 | — | — | EP | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-112437772-B | Bcl-2 inhibitors | 百济神州有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| CN-111217802-B | Histone acetylase p300 inhibitor and application thereof | 海创药业股份有限公司 | 2021-10-08 | — | — | CN | disclosed |
| EP-3889138-A1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2021-10-06 | — | — | EP | disclosed |
| CN-112437772-A | Bcl-2 inhibitors | 百济神州有限公司 | 2021-03-02 | — | — | CN | disclosed |
| WO-2020108500-A1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | 成都海创药业有限公司 | 2020-06-04 | — | — | WO | disclosed |
| CN-111217802-A | Histone acetylase p300 inhibitor and application thereof | 成都海创药业有限公司 | 2020-06-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | EP300, HDAC1, HDAC11 | TACR1 4836/4885MEN1 1820/4885KMT2A 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.